Indaptus Therapeutics, Inc. Financing Cash Flow
Indaptus Therapeutics, Inc. (INDP) reported Financing Cash Flow of $11.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Indaptus Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $5.87M, a 225.92% increase year-over-year.
- Indaptus Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $2.24M, a 13.76% decline year-over-year.
- Indaptus Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $6.28M, a 16411.32% increase year-over-year.
- Indaptus Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $3.15M, a 897.13% increase year-over-year.
- Indaptus Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $17.54M, a 269.51% increase from fiscal 2024.
- Indaptus Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $4.75M.
- Indaptus Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2021 was $48.34M, a 4055.66% increase from fiscal 2020.
- Indaptus Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2020 was $1.16M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $11.98M 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | $5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $8.11M derived: sum of 2 quarters · filed 2026-03-17 | $14.39M derived: sum of 3 quarters · filed 2026-08-13 | $17.54M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $8.52M derived: sum of 2 quarters · filed 2026-08-13 | $11.67M 10-Q · filed 2025-11-12 | $13.47M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $6.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $9.44M 10-Q · filed 2026-08-13 | $11.24M derived: sum of 3 quarters · filed 2026-08-13 | $13.83M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $3.15M 10-Q · filed 2026-05-15 | $4.95M derived: sum of 2 quarters · filed 2026-05-15 | $7.55M derived: sum of 3 quarters · filed 2026-05-15 | $7.58M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.39M derived: sum of 2 quarters · filed 2026-03-17 | $4.43M derived: sum of 3 quarters · filed 2026-03-17 | $4.75M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $2.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.63M derived: sum of 2 quarters · filed 2025-11-12 | $2.95M 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $38.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $354.11K 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $316.05K 10-Q · filed 2025-05-14 | ||||
| 2021-12-31 | $363.06K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $42.89M derived: sum of 2 quarters · filed 2023-03-17 | $44.66M derived: sum of 3 quarters · filed 2023-03-17 | $48.34M 10-K · filed 2023-03-17 | |
| 2021-09-30 | $42.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $44.30M derived: sum of 2 quarters · filed 2022-11-10 | $47.97M 10-Q · filed 2022-11-10 | $47.97M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $5.45M 10-Q · filed 2022-08-08 | $10.86M 10-Q · filed 2021-08-16 | $5.45M derived: sum of 3 quarters · filed 2022-08-08 | -$3.99M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $3.67M 10-Q · filed 2022-05-12 | $3.67M derived: sum of 2 quarters · filed 2022-05-12 | -$5.77M derived: sum of 3 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$3.96K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$9.44M derived: sum of 2 quarters · filed 2022-03-21 | $1.16M 10-K · filed 2022-03-21 | ||
| 2020-09-30 | -$9.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $1.17M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $10.60M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |